Comparing Marinus Pharmaceuticals (NASDAQ:MRNS) & BioDelivery Sciences International (BDSI)
Marinus Pharmaceuticals (NASDAQ: MRNS) and BioDelivery Sciences International (NASDAQ:BDSI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitabiliy, institutional ownership, valuation and analyst recommendations.
Earnings and Valuation
This table compares Marinus Pharmaceuticals and BioDelivery Sciences International’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Marinus Pharmaceuticals||N/A||N/A||-$26.50 million||($1.36)||-1.26|
|BioDelivery Sciences International||$40.83 million||4.40||-$35.53 million||($0.32)||-10.16|
Marinus Pharmaceuticals has higher revenue, but lower earnings than BioDelivery Sciences International. BioDelivery Sciences International is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Marinus Pharmaceuticals and BioDelivery Sciences International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioDelivery Sciences International||-0.19%||-1.45%||-0.11%|
This is a breakdown of recent ratings and target prices for Marinus Pharmaceuticals and BioDelivery Sciences International, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioDelivery Sciences International||1||0||5||0||2.67|
Marinus Pharmaceuticals presently has a consensus target price of $3.00, suggesting a potential upside of 75.44%. BioDelivery Sciences International has a consensus target price of $4.00, suggesting a potential upside of 23.08%. Given Marinus Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Marinus Pharmaceuticals is more favorable than BioDelivery Sciences International.
Risk & Volatility
Marinus Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, BioDelivery Sciences International has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
Institutional & Insider Ownership
32.7% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.3% of BioDelivery Sciences International shares are owned by institutional investors. 6.4% of Marinus Pharmaceuticals shares are owned by company insiders. Comparatively, 9.0% of BioDelivery Sciences International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
BioDelivery Sciences International beats Marinus Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.